ArticleNature communications2026
The global economic burden of diabetes for 190 countries 2021-50: a macroeconomic modelling study.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes imposes a substantial health burden, yet its macroeconomic consequences remain incompletely quantified. Here we use a health-augmented macroeconomic model to estimate output losses attributable to diabetes across 190 countries and territories during 2021-2050. We project that diabetes could reduce cumulative global output by 5.177 trillion international dollars over this period, with substantial heterogeneity in relative losses as a share of GDP across countries. Country-level burdens vary markedly, reflecting heterogeneity in demographic trends, macroeconomic conditions, diabetes prevalence, health-system capacity and treatment costs. Most projected output loss is attributable to diabetes-related disability rather than premature mortality. In this work, we provide comparable cross-country estimates of the long-run macroeconomic burden of diabetes, informing prioritization of prevention, treatment policies, and related investments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.